14,000 women at risk of fractures after the menopause to benefit from bone disease drug
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Abaloparatide (also called Eladynos and made by Theramex) increases bone density by stimulating the cells that make new bone and this reduces the risk of fracture. It can provide an alternative for people who have not responded to, or cannot tolerate, usual treatment options.
During the menopause oestrogen, the hormone that is important for maintaining bone density and strength, decreases and bone density reduces. This can lead to bone thinning, known as osteoporosis, and therefore broken bones become more common. Fractures can be very painful and limit a person's independence, and they are also associated with increased mortality.
Usual treatment for osteoporosis after menopause in people with a very high risk of fracture includes romosozumab or teriparatide followed by bisphosphonates such as alendronic acid. Abaloparatide is a clinically and cost-effective new option that can be used as an alternative.
It comes as a pre-filled pen that is injected into the muscle through the skin. This means it can be self-administered at home which is convenient for people who are prone to fractures.
It will be available for use on the NHS in England within 3 months.